- RBC Capital analyst Douglas Miehm raised the price target for Dialogue Health Technologies Inc CARE to C$10 from C$9 with the Sector Perform rating on the shares.
- Last week CARE announced the acquisition of London, U.K.-based Tictrac Ltd. for up to C$56 million (5.3x 2022E revenues). Tictrac is a SaaS-based provider of a global health and wellness platform that enables healthier living for everyone.
- Miehm views the Tictrac acquisition positively, as it strengthens Dialogue’s value proposition as a fully integrated digital health platform.
- Price Action: CARE shares are trading higher by 1.52% at C$6.00 on TSX on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
